Paper · 41585231
Baricitinib in chronic kidney disease: an exploratory analysis integrating network toxicology, molecular docking and pharmacovigilance.
Zheng R and 9 others. Front Med (Lausanne), 2025. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Baricitinib in chronic kidney disease: an exploratory analysis integrating network toxicology, molecular docking and pharmacovigilance. Papers, record 41585231. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41585231
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Baricitinib in chronic kidney disease: an exploratory analysis integrating network toxicology, molecular docking and pharmacovigilance.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References111
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30,782,187 | Targeting PI3K in cancer: mechanisms and advances in clinical trials. | Mol Cancer | 2019 | https://conductscience.org/library/papers/30782187 | PubMed |
| 2 | 38,075,191 | The Molecular Mechanism of Renal Tubulointerstitial Inflammation Promoting Diabetic Nephropathy. | Int J Nephrol Renovasc Dis | 2023 | https://conductscience.org/library/papers/38075191 | PubMed |
| 3 | 33,228,060 | Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles. | Cells | 2020 | https://conductscience.org/library/papers/33228060 | PubMed |
| 4 | 40,578,831 | Global, regional, and national burden of renal anemia, 1990 to 2019 and prediction to 2050. | Nephrol Dial Transplant | 2025 | https://conductscience.org/library/papers/40578831 | PubMed |
| 5 | 35,401,230 | Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35401230 | PubMed |
| 6 | 31,862,695 | Lipid rafts in glial cells: role in neuroinflammation and pain processing. | J Lipid Res | 2020 | https://conductscience.org/library/papers/31862695 | PubMed |
| 7 | 35,355,655 | Yishen Qingli Heluo Granule in the Treatment of Chronic Kidney Disease: Network Pharmacology Analysis and Experimental Validation. | Drug Des Devel Ther | 2022 | https://conductscience.org/library/papers/35355655 | PubMed |
| 8 | 39,669,205 | Yishen paidu pills attenuates 5/6 nephrectomy induced kidney disease via inhibiting the PI3K/AKT/mTOR signaling pathway. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39669205 | PubMed |
| 9 | 33,384,662 | Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies. | Front Endocrinol (Lausanne) | 2020 | https://conductscience.org/library/papers/33384662 | PubMed |
| 10 | 28,245,913 | A New View of Pathway-Driven Drug Resistance in Tumor Proliferation. | Trends Pharmacol Sci | 2017 | https://conductscience.org/library/papers/28245913 | PubMed |
1 to 10 of 111
See all 111 referencesCited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42,775,123 | Computational prioritization of candidate TCDD-associated targets in retinoblastoma using network toxicology and transcriptomic analysis. | Front Genet | 2026 | https://conductscience.org/library/papers/42775123 |
Source PubMed
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| EGFR | 1,956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ESR1 | 2,099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
| JAK1 | 3,716 | PubTator's text mining | https://conductscience.org/library/genes/3716 | NCBI Gene |
| JAK2 | 3,717 | PubTator's text mining | https://conductscience.org/library/genes/3717 | NCBI Gene |
| SMAD3 | 4,088 | PubTator's text mining | https://conductscience.org/library/genes/4088 | NCBI Gene |
| SRC | 6,714 | PubTator's text mining | https://conductscience.org/library/genes/6714 | NCBI Gene |
| STAT3 | 6,774 | PubTator's text mining | https://conductscience.org/library/genes/6774 | NCBI Gene |
| TGFB1 | 7,040 | PubTator's text mining | https://conductscience.org/library/genes/7040 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41585231
GET https://conductscience.org/api/papers/v1/41585231/references?page=2